

Mail Stop 3561

October 23, 2008

Mr. William F. Borne  
Chief Executive Officer  
Amedisys, Inc.  
5959 S. Sherwood Forest Blvd.  
Baton Rouge, LA 70816

**Re: Amedisys, Inc.  
Form 10-K for Fiscal Year Ended December 31, 2007  
Filed February 27, 2008  
File No. 000-24260**

Dear Mr. Borne:

We have reviewed your filing and have the following comments. Where indicated, we think you should revise your document in response to these comments. If you disagree, we will consider your explanation as to why our comment is inapplicable or a revision is unnecessary. Please be as detailed as necessary in your explanation. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. After reviewing this information, we may raise additional comments.

Please understand that the purpose of our review process is to assist you in your compliance with the applicable disclosure requirements and to enhance the overall disclosure in your filing. We look forward to working with you in these respects. We welcome any questions you may have about our comments or any other aspect of our review. Feel free to call us at the telephone numbers listed at the end of this letter.

10-K

Financial Statements

Notes to Financial Statements

1. We note you relied on the use of an independent valuation firm to assist you both in the determination of the fair value of acquired assets and liabilities (F-14) and in the performance of your annual impairment review (F-11). Please confirm in future filings that you will name the expert(s) who assisted you and file the consent(s) of the expert(s) as an exhibit. Alternatively, you may elect to revise

your disclosures in future filings to eliminate all references to the use of experts and/or independent valuations.

As appropriate, please amend your filing and respond to these comments within 10 business days or tell us when you will provide us with a response. You may wish to provide us with marked copies of the amendment to expedite our review. Please furnish a cover letter with your amendment that keys your responses to our comments and provides any requested information. Detailed cover letters greatly facilitate our review. Please understand that we may have additional comments after reviewing your amendment and responses to our comments.

We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes all information required under the Securities Exchange Act of 1934 and that they have provided all information investors require for an informed investment decision. Since the company and its management are in possession of all facts relating to a company's disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made.

In connection with responding to our comments, please provide, in writing, a statement from the company acknowledging that:

- the company is responsible for the adequacy and accuracy of the disclosure in the filing;
- staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and
- the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

In addition, please be advised that the Division of Enforcement has access to all information you provide to the staff of the Division of Corporation Finance in our review of your filing or in response to our comments on your filing.

William Borne  
Amedisys, Inc.  
October 23, 2008  
Page 3

You may contact Blaise Rhodes at (202) 551-3774 or Angela Halac at (202) 551-3311 if you have questions regarding comments on the financial statements and related matters.

Sincerely,

Tia Jenkins  
Senior Assistant Chief Accountant  
Office of Beverages, Apparel and  
Health Care Services